Live news related to ADOCIA stock (FR0011184241): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on ADOCIA mainly cover M&A activity, earnings publications et analyst notes. The stock trades at €3,84 on Euronext Paris, up 0,52% at the last update. This page lists the articles published on ADOCIA stock to track the share price, company announcements and any item likely to influence market perception.
Lyon-based biotech company Adocia, specializing in diabetes and obesity treatments, confirms compliance with all eligibility criteria for the PEA-PME.…
On Monday, during the annual scientific conference of the American Diabetes Association, Adocia presented the complete data from its phase 3 trial con…
Adocia has released its Q1 2026 financial results, showing a cash balance of EUR 12.0 million as of March 31, with a quarterly cash burn of EUR 5.1 mi…
The stock of the Lyon-based biotech company marked a significant rebound this Tuesday, April 28, reaching 4.906 euros after closing at 4.644 euros the…
Biopharmaceutical company Adocia has announced the signing of a current account advance agreement with Vester Finance, for a total amount of 6 million…
Adocia announced the completion of the Phase 3 program for BioChaperone® Lispro with its Chinese partner Tonghua Dongbao, showing positive results in …
The Lyon-based biopharmaceutical company Adocia has announced the dates for its financial publications and general assembly for the fiscal year 2026.
Lyon-based biopharmaceutical company Adocia has announced the publication dates for its financial and operational indicators for the year 2026, accord…
Biopharmaceutical company Adocia announces the filing of a patent for its AdoXLong platform, aimed at extending the action of peptides to one month.
Adocia and its partner Tonghua Dongbao have announced positive results from a Phase 3 clinical trial of BioChaperone® Lispro, an ultra-rapid insulin, …
